Latest news from Kimera Labs Inc on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/kimera-labs-files-first-fda-investigational-new-drug-ind-application-using-xoglo-for-treatment-of-ards-secondary-to-covid-19/?sc=rsin /articles/kimera-labs-files-first-fda-investigational-new-drug-ind-application-using-xoglo-for-treatment-of-ards-secondary-to-covid-19/?sc=rsin Tue, 18 Aug 2020 11:05:44 EST Kimera(r) Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo(r) isolated placental mesenchymal stem cell-based exosomes. Kimera Labs Inc